Big science for vaccine development

[...]the regulatory environment, the number of subjects and the complexity of clinical testing changed so much that only big companies with a large capacity of human and financial resources can afford to bring vaccines to the finish line. [...]once proof of concept in humans is achieved, a private i...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 32; no. 37; pp. 4705 - 4707
Main Authors Rappuoli, Rino, Medaglini, Donata
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 20.08.2014
Elsevier Limited
Subjects
Allergy and Immunology
Biomedical Research
Drug Industry
Information Dissemination
Metabolic disorders
Pharmaceutical industry
Public-Private Sector Partnerships
Science
Vaccine development
Vaccine policy
Vaccines
Vaccine development
Vaccine policy
Online AccessGet full text

Cover

More Information
Summary:[...]the regulatory environment, the number of subjects and the complexity of clinical testing changed so much that only big companies with a large capacity of human and financial resources can afford to bring vaccines to the finish line. [...]once proof of concept in humans is achieved, a private industrial partner needs to take the leadership to industrialize the process, get regulatory approval and commercialize the vaccine.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0264-410X
1873-2518
1873-2518
DOI:10.1016/j.vaccine.2014.06.071